Pfizer Inc. (NYSE:PFE) Stock Holdings Decreased by Investment House LLC

Investment House LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 17.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 19,698 shares of the biopharmaceutical company’s stock after selling 4,075 shares during the quarter. Investment House LLC’s holdings in Pfizer were worth $523,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of PFE. Koss Olinger Consulting LLC lifted its holdings in Pfizer by 2.6% during the 4th quarter. Koss Olinger Consulting LLC now owns 80,401 shares of the biopharmaceutical company’s stock worth $2,133,000 after buying an additional 2,020 shares during the last quarter. Vinva Investment Management Ltd raised its position in shares of Pfizer by 43.2% during the 4th quarter. Vinva Investment Management Ltd now owns 277,023 shares of the biopharmaceutical company’s stock valued at $7,319,000 after acquiring an additional 83,558 shares in the last quarter. Bank of Marin lifted its stake in Pfizer by 67.3% during the fourth quarter. Bank of Marin now owns 14,100 shares of the biopharmaceutical company’s stock worth $374,000 after purchasing an additional 5,670 shares during the last quarter. VSM Wealth Advisory LLC acquired a new position in Pfizer in the fourth quarter worth $72,000. Finally, Compass Ion Advisors LLC increased its stake in Pfizer by 55.6% during the fourth quarter. Compass Ion Advisors LLC now owns 24,295 shares of the biopharmaceutical company’s stock valued at $645,000 after purchasing an additional 8,677 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on PFE. UBS Group decreased their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Down 0.5 %

PFE stock opened at $26.18 on Thursday. The firm’s 50-day moving average is $26.19 and its two-hundred day moving average is $27.08. The company has a market capitalization of $148.35 billion, a price-to-earnings ratio of 18.57, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the firm posted $0.10 earnings per share. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.